facebook
eISSN: 2084-9893
ISSN: 0033-2526
Dermatology Review/Przegląd Dermatologiczny
Bieżący numer Archiwum Artykuły zaakceptowane O czasopiśmie Zeszyty specjalne Rada naukowa Bazy indeksacyjne Prenumerata Kontakt Zasady publikacji prac Standardy etyczne i procedury
Panel Redakcyjny
Zgłaszanie i recenzowanie prac online
SCImago Journal & Country Rank
6/2023
vol. 110
 
Poleć ten artykuł:
Udostępnij:
streszczenie artykułu:
Opis przypadku

Use of rituximab in the treatment of pemphigus vulgaris in a juvenile patient

Hanna Róża Cisoń
1
,
Wojciech Baran
1
,
Rafał Białynicki-Birula
1

  1. Department of Dermatology, Venereology and Allergology, Medical University of Wroclaw, Wroclaw, Poland
Dermatol Rev/Przegl Dermatol 2023, 110, 694-697
Data publikacji online: 2024/02/26
Pełna treść artykułu Pobierz cytowanie
 
Metryki PlumX:


Introduction:
Pemphigus vulgaris is a chronic autoimmune blistering disorder characterised by the production of autoantibodies against desmogleins, resulting in intraepithelial blister formation. Despite advancements in treatment options, some patients experience disease progression and an inadequate response to conventional therapies. Rituximab, a monoclonal chimeric antibody targeting CD20 on B-cells, has shown promise as an alternative therapeutic option.

Case report:
In this case report, we present the management of a 14-year-old child with pemphigus vulgaris who exhibited disease progression despite conventional treatment modalities. The patient was administered rituximab therapy, resulting in significant clinical improvement and disease control.

Conclusions:
The utilisation of rituximab as an adjunct or alternative therapy in refractory pemphigus cases offers a valuable treatment option. Further studies and long-term follow-up are necessary to determine the optimal dosing regimen and evaluate the safety and efficacy of rituximab in paediatric pemphigus patients.



© 2024 Termedia Sp. z o.o.
Developed by Bentus.